Business Combinations - Additional Information (Detail)					1 Months Ended			3 Months Ended	12 Months Ended
	Oct. 07, 2025 USD ($) NonTradableContingentValueRightCvrPerShare $ / shares	Sep. 23, 2025 USD ($)	Jul. 08, 2024 USD ($) Employees	May 28, 2024	Jul. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Aug. 31, 2019	Dec. 31, 2025 USD ($) $ / shares	Dec. 31, 2025 USD ($) $ / shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Business Acquisition [Line Items]
Total purchase price									$ 421,638,000
Fair value changes									1,029,000
Goodwill								$ 67,595,000	67,595,000	$ 1,931,000
Total revenues									348,966,000	285,504,000	$ 198,962,000
Net operating losses									$ 38,801,000	$ 72,587,000	$ 8,678,000
Number of pulmatrix employees which began employment | Employees			13
Incremental borrowing rate			7.25%					7.60%	7.60%	7.30%
Letters of credit secured by cash held in restricted depository account						$ 700,000
Lease term extension period						Effective Date through November 30, 2033
Lease monthly payments						$ 100,000
Percentage of annual increment on lease						3.00%
Maturity date							Dec. 31, 2025
scPharmaceuticals Inc.
Business Acquisition [Line Items]
Effective date of acquisition	Oct. 07, 2025
Acquisition price per share in cash | $ / shares	$ 5.35
Non-tradable contingent value right ("CVR") per share | NonTradableContingentValueRightCvrPerShare	1
Amount per CVR in cash upon achievement of certain regulatory and net sales milestones | $ / shares	$ 1
Equity value	$ 303,800,000
Total purchase price	363,500,000
Aggregate repayment and buyout amount	82,600,000
Fair value changes								$ 1,029,000
Goodwill	65,664,000							65,664,000	$ 65,664,000
Total revenues									23,200,000
Net operating losses									(9,900,000)
Principal amount		$ 10,000,000
Interest rate SOFR		4.75%
Stated interest rate		9.00%
Maturity date		Nov. 06, 2025
Inventory	$ 11,200,000							$ 11,200,000	11,200,000	$ 13,300,000
Transaction costs									$ 9,700,000
scPharmaceuticals Inc. | Milestone 1 September 30, 2026
Business Acquisition [Line Items]
Amount per CVR in cash upon achievement of milestones | $ / shares								$ 0.75	$ 0.75
scPharmaceuticals Inc. | Milestone 1 December 31, 2026
Business Acquisition [Line Items]
Amount per CVR in cash upon achievement of milestones | $ / shares								0.5	0.5
scPharmaceuticals Inc. | Milestone 1 June 30, 2027
Business Acquisition [Line Items]
Amount per CVR in cash upon achievement of milestones | $ / shares								0.25	$ 0.25
scPharmaceuticals Inc. | Milestone 2
Business Acquisition [Line Items]
Minimum milestone net sales									$ 110,000,000
Net sales									$ 120,000,000
Amount per CVR in cash upon achievement of milestones | $ / shares								0.25	$ 0.25
scPharmaceuticals Inc. | Minimum | Milestone 2
Business Acquisition [Line Items]
Net sales									$ 110,000,000
Amount per CVR in cash upon achievement of milestones | $ / shares								0.1	$ 0.1
scPharmaceuticals Inc. | Maximum
Business Acquisition [Line Items]
Consideration per share in cash | $ / shares	$ 6.35
scPharmaceuticals Inc. | Maximum | Milestone 2
Business Acquisition [Line Items]
Net sales									$ 120,000,000
Amount per CVR in cash upon achievement of milestones | $ / shares								$ 0.25	$ 0.25
Pulmatrix, Inc
Business Acquisition [Line Items]
Asset acquisition, date of acquisition agreement				May 28, 2024
Asset acquisition, effective date of acquisition			Jul. 08, 2024
Fair value of iSPERSE license			$ 4,300,000
Lease monthly payments					$ 101,282
Percentage of annual increment on lease					3.00%
IPR&D
Business Acquisition [Line Items]
Fair value discount rate percent	23.00%
Royalty rate percent	10.00%
Developed Technology
Business Acquisition [Line Items]
Fair value discount rate percent	23.00%
Royalty rate percent	10.00%
Developed Technology | scPharmaceuticals Inc.
Business Acquisition [Line Items]
Acquired intangible assets useful life								11 years 2 months 12 days	11 years 2 months 12 days